STUDY OF HALOPERIDOL AND PIMOZIDE IN TOURETTE SYNDROME

氟哌啶醇被认为是治疗 图雷特综合征（TS），虽然没有双盲研究， 与安慰剂或其他精神抑制剂相比的有效性。 考虑到这一需求，我们建议进行一项随机、双盲、 平行研究比较的临床有效性和不良反应 氟哌啶醇、匹莫齐特和安慰剂。 假设， 积极地说，氟哌啶醇和匹莫齐特将改善症状， 和症状的TS显着超过安慰剂， 与氟哌啶醇相比， 运动不能的不利影响。 第二个目的是衡量和评估 与TS治疗相关的认知障碍的性质， 氟哌啶醇和匹莫齐特，并回顾性研究 药物剂量、改善、不良反应和选定的人口统计学之间 与疾病相关的变量。 这项研究将随机分配病人 三种治疗条件之一。 两名临床医生将同意 诊断和严重程度评级。 多项改进措施， 不良反应将由治疗医生、患者和 两名独立法官根据他们对病人录像带的评分。 将进行认知测试，以测量对认知的影响 氟哌啶醇匹莫齐特和安慰剂 图雷特综合征是一种慢性的，经常致残的疾病， 童年. 这些症状通常很奇怪， 可能会限制社会心理、教育和职业功能。 严重 症状可能导致低自尊，社会退缩，成为 回家和住院 慢性药物管理往往是 需要抑制抽搐症状并允许有效的功能。 医生有责任防止由于 慢性药物管理，特别是如果这些干扰学习 在已经患有严重残疾的患者身上。 的目的 这项研究提供的数据将允许选择最少的 损害，但最有效的药物治疗TS和一个 可能的最佳剂量范围，以防止有害的副作用。

Haloperidol is considered to be the drug of choice for the treatment of Tourette Syndrome (TS) although no double-blind studies of its effectiveness compared to placebo or other neuroleptics have been done. With this need in mind, we propose to conduct a randomized, double-blind, parallel study comparing the clinical effectiveness and adverse effects of haloperidol, pimozide and placebo in 90 TS patients. The hypotheses, stated positively, are that haloperidol and pimozide will improve the signs and symptoms of TS significantly more than placebo and that pimozide compared to haloperidol will yield significantly more improvement and fewer akinesic adverse effects. Secondary purposes are to measure and assess the nature of the cognitive impairment associated with the treatment of TS with haloperidol and pimozide, and to retrospectively study the relationship between drug dosage, improvement, adverse effects, and selected demographic and illness-related variables. The study will randomly assign the patients to one of the three treatment conditions. Two clinicians will agree on diagnosis and rating of severity. Multiple measures of improvement and adverse effects will be rated by the treating physician, the patient and two independent judges based on their ratings of videotapes of patients. Tests of cognition will be administered to measure the effect on cognition of haloperidol, pimozide and placebo. Tourette syndrome is a chronic, often disabling illness with onset in childhood. The often bizarre and socially limiting nature of the symptoms can restrict psychosocial, educational and vocational functioning. Severe symptoms can result in low self-esteem, social withdrawal, becoming homebound, and hospitalization. Chronic drug administration is often required to suppress tic symptoms and permit effective functioning. Physicians have a responsibility to prevent disabling adverse effects due to chronic drug administration, especially if these interfere with learning in patients already afflicted with a severe disability. The purpose of this study is to provide data which will allow selection of the least impairing but most effective medication for the treatment of TS and a possible range of optimal dosage to prevent harmful adverse effects.